The development of drug-resistant cancers is considered to be the most significant obstacle to the cure of cancer today. Nearly half of all patients with cancer suffer from tumours that are intrinsically resistant to chemotherapy, and most of the remaining half develop drug resistance during the course of their treatment. This book reviews the mechanisms and clinical implications of drug resistance in cancer with unrivalled authority. Chapters cover topics of current clinical concern, including multiple drug resistance and its reversal, topoisomerase drugs, apoptosis, dose intensity and escalation, gene therapy and haematopoietic support. The authors are among the leading clinicians and investigators in the field. These authoritative volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management of cancer.

‘… recommended for clinical oncologists, who will find extensive information on this topic which is seldom to be found in oncology textbooks.’

Source: Annals of Oncology

‘The strength of the book is related to the weaknesses described above. Multiple knowledgeable authors review topics related to drug resistance. Some of the authors primarily review their own work, while others try and update the reader on significant contributions from others. The book accomplishes what it is supposed to; it provides a way for the reader to learn and somewhat update his/her knowledge of drug resistance.’

Howard Bailey - Madison, Wisconsin